Arch Biopartners Exclusively Licenses CU Peptide Surface Technology

AURORA, Colo. – December 7, 2010 – Arch Biopartners Inc. (“Arch” or the “Company”) announced today that it has obtained an exclusive license for a patent pending in the area of peptides and solid surfaces owned by the University of Colorado (“CU”) and emanating from the Program in Structural Biology and Biophysics, headed by Dr. Robert Hodges.

The Company has agreed to pay $36,000 USD as consideration for the license. Additionally, the Company has agreed to issue 150,000 common shares to CU in the event the Company identifies a product covered by the patent that is ready to be advanced into formal clinical or commercial development. Future royalty payments by the Company to CU relating to the licensed patent will depend on future sales. The Company’s patent attorney is now responsible for completing the prosecution of the patent filing with the US Patent and Trademarks Office.

See also: Arch Biopartners Acquires Option to License Anti-Cancer Compounds from CU.

About Arch Biopartners
Arch Biopartners is a portfolio based biotechnology company established to develop new products and technology for sale to pharmaceutical and industrial companies. For more information on the Company, please consult the other public documents including all press releases, management information circular, financial statements and management discussion and analysis filed on SEDAR at www.sedar.com. The company’s website address is www.archbiopartners.com.

Forward-Looking Statements
All statements, other than statements of historical fact, in this news release are forward looking statements that involve various risks and uncertainties, including, without limitation, statements regarding the future plans and objectives of the Company. There can be no assurance that such statements will prove to be accurate. Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. The Company assumes no obligation to update forward-looking statements should circumstances or management’s estimates or opinions change.